Dimagi Inc.: Clinical Trials

11 trials sponsored by Dimagi Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 1 enrolling by invitation, 1 unknown. 8 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable8Completed 6, Enrolling by invitation 1, Unknown 1
Phase 11Completed 1
Phase 21Completed 1
Phase 41Completed 1

Follow Dimagi Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Measurement-Based Peer Supervision App for Non-Specialist Providers
MBPS App - Training of Mental Health Professionals, Training of Frontline Health Workers
Not applicableEnrolling by invitationDimagi Inc.552025-05-152026-04-20
A Chatbot To Support Substance Use Recovery
chatbot - Opiate-Related Disorders, Opiate Substitution Treatment
Phase 1 / Phase 2CompletedDimagi Inc.552025-03-072026-07-27
Adapting and Evaluating a Brief Advice Tobacco Intervention in High-Reach, Low-Resource Settings in India
LifeFirst SWASTH brief advice intervention - Tobacco Use Cessation
Not applicableCompletedHarvard School of Public Health (HSPH)46932023-11-012026-02-27
PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS
PlusCare - HIV/AIDS
Not applicableCompletedDimagi Inc.652019-01-022023-10-26
m-Palliative Care Link: Improving Palliative Care for Late Stage Tanzanian Cancer Patients
mPCL, Usual Care - Cancer
Not applicableCompletedSusan Miesfeldt982018-06-152021-10-14
Mobile -Solutions Aiding Knowledge for Health Improvement
Mobile phone counselling - Under Nutrition
Not applicableUnknownLata Medical Research Foundation, Nagpur27282017-02-012019-03-15
ScreenFlow: Strategy for Finding Cases of Moderate-to-Severe COPD
Pulmonary Disease, Chronic Obstructive
CompletedDimagi Inc.3992015-09-012018-02-01
Antiretroviral Adherence and Quality-of-life Support for HIV+ Patients in India With Twice-daily Interactive Voice Response (IVR) Calls With Health and Mental Health Messaging Compared to Weekly IVR Survey Only Control Condition: The Mobile-messaging Adherence and Support for Health Study, India.
Daily IVR Calls Intervention, Weekly IVR Survey Only - HIV/AIDS
Not applicableCompletedUniversity of California, Los Angeles4002014-04-012015-06-08
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
Darunavir, Etravirine, Emtricitabine/tenofovir disoproxil fumarate - HIV-1 Infection
Phase 4CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections5452013-02-222019-03-15
China Adherence Through Technology Study
adherence feedback, standard of care - Medication Adherence
Not applicableCompletedBoston University1202012-11-012017-04-21
ARemind: A Personalized System to Remind for Adherence
Beeper, ARemind - Medication Adherence
Not applicableCompletedDimagi Inc.702011-10-012019-03-20

Conditions studied

Acquired Immunodeficiency Syndrome (3)  ·  Medication Adherence (3)  ·  Depression (2)  ·  Anxiety Disorders (1)  ·  Communication (1)  ·  Lung Diseases (1)  ·  Neoplasms (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Tobacco Use (1)  ·  Tobacco Use Cessation (1)

Interventions

Darunavir (1)  ·  Data Collection (1)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)  ·  Raltegravir Potassium (1)  ·  Ritonavir (1)  ·  Standard of Care (1)  ·  bactericidal permeability increasing protein (1)  ·  etravirine (1)

Countries

United States (5)  ·  India (4)  ·  Brazil (1)  ·  China (1)  ·  Haiti (1)  ·  Kenya (1)  ·  Malawi (1)  ·  Peru (1)  ·  South Africa (1)  ·  Tanzania (1)  ·  Thailand (1)  ·  Uganda (1)  ·  Zimbabwe (1)

Top investigators

Amy Baranoski, M.D. (1)  ·  Archana B Patel, MD, PhD (1)  ·  Beatriz Grinsztejn, MD, PhD (1)  ·  Himanshu Gupte, MBBS, MD (1)  ·  Jonathan Jackson, MEng (1)  ·  Jonathan L Jackson, MEng (1)  ·  Lora Sabin, PhD (1)  ·  Peter Mugyenyi, MB ChB, FRCP, DSc (1)  ·  Susan Miesfeldt, MD (1)  ·  Vikram S Kumar, M.D. (1)  ·  Vikram S Kumar, MD (1)  ·  Y. Xian Ho, PhD (1)  ·  Yun Xian Ho, PhD (1)

Results publications

PMID 30462688, PMID 31371262, PMID 31528850, PMID 32049773, PMID 33437832, PMID 36039892, PMID 36409541

NIH funding

R21TW010190 (1), R44DA050218 (1), R44MH080655 (1), R44MH130305 (1), U01AI068636 (1)